title: Clinical course of patients treated for advanced ovarian carcinoma without surgical intervention.
abstract: OBJECTIVE
  To describe the clinical course and outcome of patients with non-surgically-treated advanced ovarian cancer attending a single institute.
  
  
  RESULTS
  We reviewed the medical charts of all patients with advanced epithelial ovarian cancer who underwent chemotherapy at a tertiary medical center between January 2005 and December 2010 but were never operated. Data on patient characteristics, disease course, and outcome were collected from patient files. Sixteen patients met the inclusion criteria. Eight (50%) were diagnosed with apparent FIGO stage IIIC disease, and 8 with stage IV. Five patients (31%) achieved a complete clinical response, and 11 (69%) achieved a partial response. Among the complete responders, the median disease-free interval was 8 months (range 7-11 months). In all of them, the disease recurred and second-line chemotherapy was administered. Of them, four (80%) achieved a second complete response. Partial responders had up to four lines of chemotherapy, with continued disease progression. The median overall survival of the whole group was 19.5 months, and of the complete responders, 28 months.
  
  
  CONCLUSIONS
  Most patients with advanced ovarian carcinoma who will not undergo surgery respond only partially to first-line chemotherapy. Having no surgery is associated with a short disease-free interval.
authors: Gynecologic Oncology Division, The Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva, Israel. eitanr@clalit.org.il
authors: Ram
authors: R
authors: Eitan
authors: Haim
authors: H
authors: Krissi
authors: Hanoch
authors: H
authors: Levavi
authors: Gad
authors: G
authors: Sabah
authors: Yoav
authors: Y
authors: Peled
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D016896:Treatment Outcome
references: Semin Oncol. 2005 Aug;32(4 Suppl 6):S4-8
references: 16143161
references: J Clin Oncol. 2002 Mar 1;20(5):1248-59
references: 11870167
references: N Engl J Med. 2010 Sep 2;363(10):943-53
references: 20818904
references: Gynecol Oncol. 1998 Dec;71(3):431-6
references: 9887245
references: Best Pract Res Clin Obstet Gynaecol. 2002 Aug;16(4):585-96
references: 12413936
references: Int J Gynecol Cancer. 2003 Nov-Dec;13(6):735-40
references: 14675308
references: Cancer. 2009 Mar 15;115(6):1234-44
references: 19189349
references: Gynecol Oncol. 2006 Dec;103(3):1070-6
references: 16875720
references: Ann Oncol. 2005;16 Suppl 8:viii7-viii12
references: 16239238
references: Obstet Gynecol. 2006 Jan;107(1):77-85
references: 16394043
references: N Engl J Med. 2006 Jan 5;354(1):34-43
references: 16394300
references: Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80
references: 8166218
references: Gynecol Oncol. 1990 Jun;37(3):327-31
references: 2351315